Rezolute (RZLT) Other financing activities (2012 - 2025)
Rezolute recorded quarterly Other financing activities of $35000.0 in Q3 2025, down 92.47% quarter-over-quarter from $465000.0 in Q2 2025, and down 93.92% year-over-year from $576000.0 in Q3 2024.
Rezolute's Other financing activities history runs 10 years deep, the most recent figure standing at $35000.0 for Q3 2025.
- In Q3 2025, Other financing activities fell 93.92% year-over-year to $35000.0; the TTM figure through Mar 2026 stood at $500000.0 (down 18.83% YoY), while the FY2025 annual figure was $1.1 million, up 236.19% from the prior year.
- Other financing activities came in at $35000.0 for Q3 2025 at Rezolute, down from $465000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $662000.0 in Q2 2021 to a low of -$3.5 million in Q1 2021.
- A 4-year average of -$159333.3 and a median of $104000.0 in 2021 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities tumbled 131.07% in 2021 and soared 2013.64% in 2025, its largest moves.
- Rezolute's Other financing activities stood at $104000.0 in 2021, then surged by 44.23% to $150000.0 in 2022, then slumped by 88.0% to $18000.0 in 2024, then surged by 94.44% to $35000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $35000.0, $465000.0, and $18000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Dec 31, 2024 | 18,000.00 |
| Dec 31, 2024 | 18,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Sep 30, 2021 | 104,000.00 |
| Sep 30, 2021 | 104,000.00 |
| Jun 30, 2021 | 662,000.00 |
| Jun 30, 2021 | 662,000.00 |
| Mar 31, 2021 | -3.47 Mn |
| Mar 31, 2021 | -3.47 Mn |
| Dec 31, 2020 | 3.54 Mn |
| Dec 31, 2020 | 3.54 Mn |
| Mar 31, 2020 | -1.50 Mn |
| Mar 31, 2020 | -1.50 Mn |
| Dec 31, 2019 | 21,000.00 |
| Dec 31, 2019 | 21,000.00 |
| Sep 30, 2019 | 1.48 Mn |
| Sep 30, 2019 | 1.48 Mn |
| Sep 30, 2017 | 60,000.00 |
| Sep 30, 2017 | 60,000.00 |
| Mar 31, 2014 | 128,300.00 |
| Mar 31, 2014 | 128,300.00 |
| Dec 31, 2013 | 142,000.00 |
| Dec 31, 2013 | 142,000.00 |
| Jun 30, 2013 | 157,500.00 |
| Jun 30, 2013 | 157,500.00 |
| Mar 31, 2013 | -145,000.00 |
| Mar 31, 2013 | -145,000.00 |
| Dec 31, 2012 | 70,000.00 |
| Dec 31, 2012 | 70,000.00 |
| Sep 30, 2012 | 75,000.00 |
| Sep 30, 2012 | 75,000.00 |
| Jun 30, 2012 | 84,500.00 |
| Jun 30, 2012 | 84,500.00 |